Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/220662
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

Effects of immunonutrition in advanced human immunodeficiency virus disease: A randomized placebo-controlled clinical trial (promaltia study)

AuthorsSerrano-Villar, Sergio; Lagarde, María de; Vázquez-Castellanos, Jorge F.; Vallejo, Alejandro; Bernadino, José I.; Madrid, Nadia; Matarranz, Mariano; Díaz-Santiago, Alberto; Gutiérrez, Carolina; Cabello, Alfonso; Villar-García, Judit; Blanco, José Ramón; Bisbal, Otilia; Sainz, Talía; Moya, Andrés; Moreno, Santiago; Gosalbes, María José; Estrada, Vicente
KeywordsMicrobiota
Inflammation
CD4 T cells
Immunoactivation
Probiotics
Issue Date2019
PublisherOxford University Press
CitationClinical Infectious Diseases 68(1): 120–130 (2019)
Abstract[Background]: While nutritional interventions with prebiotics and probiotics seem to exert immunological effects, their clinical implications in human immunodeficiency virus (HIV)–infected subjects initiating antiretroviral therapy (ART) at advanced HIV disease remain unclear.
[Methods]: This was a pilot multicenter randomized, placebo-controlled, double-blind study in which 78 HIV-infected, ART-naive subjects with <350 CD4 T cells/μL or AIDS were randomized to either daily PMT25341 (a mixture of synbiotics, omega-3/6 fatty acids and amino acids) or placebo for 48 weeks, each in combination with first-line ART. Primary endpoints were changes in CD4 T-cell counts and CD4/CD8 ratio from baseline to week 48 and safety. Secondary endpoints were changes in markers of T-cell activation, bacterial translocation, inflammation, and α and β microbiota diversity.
[Results]: Fifty-nine participants completed the follow-up with a mean CD4+ T-cell count of 221 ± 108 cells/μL and mean CD4/CD8 ratio of 0.26 ± 0.19. PMT25341 was well tolerated, without grade 3–4 adverse effects attributable to the intervention. While most of the assessed biomarkers improved during the follow-up in both arms, PMT25341-treated subjects did not experience any significant change, compared to placebo-treated subjects, in mean CD4+ T-cell count change (278 vs 250 cells/μL, P = .474) or CD4/CD8 ratio change (0.30 vs 0.32, P = .854). Similarly, we did not detect differences between treatment arms in secondary endpoints.
[Conclusions]: In HIV-infected patients initiating ART at advanced disease, the clear immunological benefits of ART were not enhanced by this nutritional intervention targeting the gut-associated lymphoid tissue and microbiota.
[Clinical Trials Registration]: NCT00870363.
Publisher version (URL)https://doi.org/10.1093/cid/ciy414
URIhttp://hdl.handle.net/10261/220662
DOI10.1093/cid/ciy414
ISSN1058-4838
E-ISSN1537-6591
Appears in Collections:(I2SysBio) Artículos

Files in This Item:
File Description SizeFormat
accesoRestringido.pdf59,24 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work

SCOPUSTM   
Citations

21
checked on Jan 18, 2022

WEB OF SCIENCETM
Citations

20
checked on Jan 18, 2022

Page view(s)

134
checked on Jan 25, 2022

Download(s)

14
checked on Jan 25, 2022

Google ScholarTM

Check

Altmetric

Dimensions


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.